Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis

T.C. Minderhoud¹*, C. Spruyt², S. Huisman², E. Oskam², S.C.E. Schuit³, M.D. Levin¹

Departments of ¹Internal Medicine and ²Emergency Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands, ³Departments of Internal Medicine and Emergency Medicine, Erasmus Medical Center, Rotterdam, the Netherlands, *corresponding author: tel.: +31 (0)20-4444444, email: tannetje@gmail.com

ABSTRACT

Objective: To study the presence of bacterial disease and antibiotic use in patients in the emergency department (ED) included in the local sepsis protocol.

Methods: An observational retrospective cohort study. Adults aged > 18 years, presenting to the ED of a large teaching hospital, from I January to I June 2011, with more than two SIRS criteria and a clinical suspicion of sepsis were included.

Results: Bacterial disease was suspected or confirmed in only 71% of all the patients with suspected sepsis (2008 definition) and consequently treated with antibiotics. Most of these patients (58%) suffered from systemic inflammatory response syndrome (SIRS) without signs of organ dysfunction, hypotension or hypoperfusion. Despite absence of bacterial disease in 29% of the patients after rigorous diagnostics, median antibiotic treatment in this group was still seven days (IQR 4-10).

Conclusions: Standard sepsis detection using SIRS criteria and clinical suspicion identified patients with suspected or confirmed bacterial disease in 71% of the cases. A significant proportion of patients were exposed to prolonged antibiotic use without proof of bacterial disease. This study illustrates the difficulties in correctly identifying bacterial disease and sepsis, and shows that overuse of antibiotics may be the consequence.

K E Y W O R D S

Sepsis, SIRS, anti-infective agents, antibiotics, inappropriate subscribing, stewardship

INTRODUCTION

Over the last decade, sepsis has been increasingly recognised as a major cause of death. After Rivers' publication and the start of the Surviving Sepsis Campaign, early detection and treatment has become a general endeavour with a special focus on the early administration of antibiotics.1 It should be noted that current evidence regarding early treatment with antibiotics was founded on studies including only patients with severe sepsis (mostly needing ICU treatment) or septic shock.1-4 However, in the effort to avoid delays in identifying sepsis many emergency departments (EDs) have started using the criteria of systemic inflammatory response syndrome (SIRS) and a clinical suspicion of infection as a way to screen their patients. The difficulty in identifying severe sepsis is that testing for organ damage (for example: renal function) takes time, whereas the recommendation is to treat severe sepsis within one hour (2012 Sepsis Guidelines⁵). Under the presumption that this waiting time may harm the patient, patients are increasingly treated with antibiotics without awaiting (all) the test results.

The Surviving Sepsis Guidelines of 2004 recommended administration of antibiotics in patients with severe sepsis or septic shock. The 2008 guideline did not give guidance as to how patients should be screened, but the 2012 guideline recommended screening of potentially infected seriously ill patients. The proposed instrument to screen for severe sepsis was an instrument based on SIRS criteria and clinical judgment, which was, however, only validated in ICU patients.³

From the very start, the SIRS criteria were criticised as defining condition for sepsis and recent publications refuelled the discussion.⁶⁻⁸ In February 2016, sepsis was redefined, removing the SIRS criteria and adding that the

© Van Zuiden Communications B.V. All rights reserved.

term sepsis had to be reserved for patients with severe organ dysfunction. The term 'severe' sepsis was dismissed and replaced by sepsis-3 and septic shock.⁹ However, SIRS criteria are still in use in clinical practice.

This study was undertaken to evaluate current practice and study the likelihood of bacterial infection in patients treated for sepsis in the ED according to the SIRS criteria. To address issues regarding antimicrobial stewardship, duration of antibiotic therapy was also evaluated.

METHODS

Study design and setting

A retrospective analysis was conducted using a cohort of consecutive adult patients presenting to the ED of the Albert Schweitzer Hospital (a large teaching hospital in Dordrecht, the Netherlands) from I January to 30 June 2011.

Inclusion

Patients diagnosed with sepsis (2008 definition) according to two or more SIRS criteria and a clinical suspicion of an infection, as assessed by the resident or ED physician, who received antibiotics upon admission were eligible.

Data collection

Data regarding vital parameters were extracted from the standard protocol form if completely filled out. All additional and missing data were extracted by hospital chart review. If more than one measurement of parameters was done in the ED, the most aberrant measurement was used in the analysis (the lowest BP recorded in the ED, or the highest respiratory rate or pulse). The primary investigator, as well as authors Spruyt and Huisman, performed the data extraction. The primary investigator then checked the data and in case of doubt regarding the primary outcome measures the case was discussed between the primary investigator and Dr. Levin until consensus was reached. Consensus was reached in all 37 patients that were discussed.

Definitions

The definitions for SIRS, sepsis, severe sepsis, sepsis-induced hypotension and septic shock were derived from the guidelines of the Surviving Sepsis Campaign in 2008. For the sake of clarity, in this article sepsis conform the old criteria will be referred to as sepsis and if referring to the new definition, sepsis-3 will be used.

The criteria to define confirmed or suspected bacterial infection were derived from an article by Limper,¹⁰ as displayed in *figure 1*. In addition to these criteria another criterion, as found in previous literature, was added for further clarification of suspected bacterial

disease: 'Clinically documented infection: presence of gross purulence or an abscess (anatomical and/or by imaging and/or histological evidence), which may not be microbiologically documented if the culture remains sterile due to antibiotic therapy.'^{II}

Outcome measures

Primary outcome measures were the number of patients with confirmed or suspected bacterial infection as assessed by the primary investigator using predefined criteria (stated above) and days of antibiotic use in these patients. Secondary outcome measures were severity of sepsis, rate of ICU admission, and mortality.

Data analysis

Results are expressed as mean \pm standard deviation (SD), or median \pm inter-quartile range (IQR) depending on normality of the data. Comparison between patients with and without bacterial infection was performed using the χ^2 test for categorical variables and the Students t-test (equal variances) or nonparametric Mann-Whitney U test for continuous data with non-normality. Statistical analyses were carried out using IBM SPSS 22.0.0 for OSX (SPSS, Chicago, IL). Missing data were excluded list-wise.

Ethics

The local institutional ethics review board approved the study design and a waiver for the retrieval of informed consent was obtained.

RESULTS

Patients and likelihood of bacterial infection

From 1 January 2011 to 30 June 2011, a total of 269 patients were diagnosed with sepsis (2008 definition) in the ED and received antibiotic treatment in the ED. *Table 1* shows the baseline characteristics and main outcome measures. Retrospective analysis of clinical signs, cultures and other investigations using predefined criteria¹⁰ (*figure 1*) showed a confirmed bacterial infection in 98 (36%) patients, of whom 51 patients had bacteraemia. In addition, 93 patients (35%) were classified as suspected bacterial disease without microbiological proof. A total of 78 patients (29%) did not have objective evidence of bacterial disease. Amongst them 21 suffered from proven or suspected viral infection. *Figure 2* illustrates the proportions.

Severity of illness

In total 71% of patients, identified with sepsis in the ED, were likely to have bacterial infection. In the group with bacterial infection, the largest proportion (58%) fulfilled criteria for sepsis, 30% fulfilled criteria for severe sepsis, and only 9.5% showed sepsis-induced hypotension. A small

IndextoreConfirmed / suspected bacterial infectionAseres, and
Males, % 89 (46.8%) 37 (46.8%) 90°* Comorbid conditions
Comorbid conditions 43 (22.6%) 24 (30.4%) ,155* Immune deficiency 28 (14.7%) 11 (13.9%) ,906* Liver cirrhosis 2 (1.1%) 2 (2.5%) ,351* Renal insufficiency 30 (15.8%) 6 (7.6%) ,680* Congestive heart failure 8 (4.2%) 5 (6.3%) ,446* Respiratory disease (COPD) 28 (14.8%) 19 (24.1%) ,600* Liboratory findings 212 (± 124.1) 66 (± 66.97) ,000* CRP maximum (first 72 hrs) 212 (± 124.1) 99.7 (± 74.0) ,507* Bilirubin 16.0 (± 10.5) 17.7 (± 38.8) ,571* Creatinine 95 (± 54.7) 85.3 (± 39.1) ,43*
Immune deficiency 43 (22.6%) 24 (30.4%) ,155* Current malignancy 28 (14.7%) 11 (13.9%) ,906* Liver cirrhosis 2 (1.1%) 2 (2.5%) ,351* Renal insufficiency 30 (15.8%) 6 (7.6%) ,880* Congestive heart failure 8 (4.2%) 5 (6.3%) ,46* Respiratory disease (COPD) 28 (14.8%) 19 (24.1%) ,060* Laboratory findings 151 (± 132.0) 66 (± 66.97) ,000° Creactive protein (CRP) day 0 151 (± 132.0) 66 (± 66.97) ,000° Bilirubin 16.0 (± 10.5) 17.7 (± 38.8) ,571° Creatinine 95 (± 54.77) 85.3 (± 39.1) ,143°
Current malignancy 28 (14,7%) 11 (13,9%) 906* Liver cirrhosis 2 (1.1%) 2 (2.5%) 3,51* Renal insufficiency 30 (15,8%) 6 (7,6%) ,080* Congestive heart failure 8 (4,2%) 5 (6,3%) ,446* Respiratory disease (COPD) 28 (14,8%) 19 (24,1%) ,060* Laboratory findings 212 (± 132,0) 66 (± 66,97) ,000^* Creactive protein (CRP) day 0 151 (± 132,0) 66 (± 66,97) ,000^* Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^* Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143*
Liver cirrhosis 2 (1.1 %) 2 (2.5 %) ,351* Renal insufficiency 30 (15,8%) 6 (7,6%) ,080* Congestive heart failure 8 (4,2%) 5 (6,3%) ,446* Respiratory disease (COPD) 28 (14,8%) 19 (24,1%) ,060* Laboratory findings J51 (± 132,0) 66 (± 66,97) ,000^ Creactive protein (CRP) day 0 151 (± 124,11) 99,7 (± 74,0) ,000^ Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^^ Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^^ Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292^
Renal insufficiency 30 (15,8%) 6 (7,6%) ,080* Congestive heart failure 8 (4,2%) 5 (6,3%) ,446* Respiratory disease (COPD) 28 (14,8%) 19 (24,1%) ,060* Laboratory findings - - - - C-reactive protein (CRP) day O 151 (± 132,0) 66 (± 66,97) ,000^ CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^ Bilirubin 16,0 (± 10.5) 17,7 (± 38.8) ,571^^ Creatinine 95 (± 54.7) 85,3 (± 39.1) ,143^^ >
Congestive heart failure 8 (4,2%) 5 (6,3%) ,446* Respiratory disease (COPD) 28 (14,8%) 19 (24,1%) ,060* Laboratory findings 5 (5,9%) ,000^* C-reactive protein (CRP) day 0 151 (± 132,0) 66 (± 66,97) ,000^* CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^* Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^* Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^* Latate 2,31 (± 2,89) 1,94 (± 1,19) ,292^*
Respiratory disease (COPD) 28 (14,8%) 19 (24,1%) ,060* Laboratory findings 5 5 5 5 C-reactive protein (CRP) day 0 151 (± 132,0) 66 (± 66,97) ,000^1 CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^1 Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^1 Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^1 Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292^1
Laboratory findings C-reactive protein (CRP) day o 151 (± 132,0) 66 (± 66,97) ,000^1 CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^1 Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^1 Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^1 Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292^1
C-reactive protein (CRP) day o 151 (± 132,0) 66 (± 66,97) ,000^1 CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^1 Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^1 Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^1 Lactate 2,31 (± 2,89) 19,4 (± 1,19) ,292^1
CRP maximum (first 72 hrs) 212 (± 124,1) 99,7 (± 74,0) ,000^1 Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571^1 Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143^1 Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292^1
Bilirubin 16,0 (± 10,5) 17,7 (± 38,8) ,571 [^] Creatinine 95 (± 54,7) 85,3 (± 39,1) ,143 [^] Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292 [^]
Creatinine 95 (± 54.7) 85.3 (± 39.1) .143 [^] Lactate 2.31 (± 2.89) 1.94 (± 1.19) .292 [^]
Lactate 2,31 (± 2,89) 1,94 (± 1,19) ,292 [^]
Bacterial outcomes
Positive blood cultures 51 (26,8%) -
Sepsis severity
Sepsis III (58.1%) 55 (70,5%) ,058*
Severe sepsis 57 (30,0%) 20 (26,3%) ,511*
Sepsis-induced hypotension 18 (9,5%) 2 (2,6%) ,057*
Septic shock 5 (2,6%) I (1,3%) ,506*
Length of stay (days) (median (IQR) 8 (5-11,7) 6 (3-10) ,006 §
ICU admission % 8 (10,1%) 17 (8,9 %)
Duration of antibiotic treatment (median + IQR) IO (7-14) 7 (4-10) ,000§
Mortality 4 (5%) 17(8,9%) ,295*

Continuous data are presented as mean ± standard deviation, unless otherwise mentioned. Categorical data as number (percentages); *chi square, ^t-test, § Mann-Whitney U test.

percentage (3%) suffered from septic shock. This means that the largest proportion of the patients identified with bacterial infection (58%) would probably not fulfil the current sepsis-3 definition, although mental status was not documented reliably in all patients.

Factors associated with patients without bacterial infection

As shown in *table 2* no significant differences in sex or comorbidity between patients with and without bacterial disease were established. The patients with bacterial disease were significantly older compared with the group

without bacterial disease (p = 0.014). C-reactive protein at day 0 and day 3 was significantly higher in patients with bacterial disease than those without (p < 0.001 in both cases).

The number of SIRS criteria was significantly associated with the presence of bacterial disease. The odds ratio of having a bacterial infection was 2.32 (CI I.3-4.3) if all four SIRS criteria were met in comparison with \leq 3 criteria. The mean arterial pressure was significantly lower in the group with proven infection (p = 0.012), even though this was not reflected in the systolic blood pressure, but rather in the diastolic blood pressure. Leucocyte count was significantly

Figure 1. Definitions of groups of infection, derived from Limper¹⁰

- Confirmed bacterial infection: positive culture result in concordance with clinical findings.
- Suspected bacterial infection: clinical findings strongly suggestive for bacterial infection, but without positive culture result; for instance, a patient with fever, purulent cough, crackles on auscultation and a lobar infiltrate on the thoracic X-ray.
- Confirmed viral infection: positive viral PCR in concordance with clinical findings.
- Suspected viral infection: clinical findings indicative of viral disease in the absence of positive bacterial cultures despite extensive culture taking and in the absence of underlying autoimmune or auto-inflammatory disease, malignancy, thromboembolic disease or medication use that could explain clinical finding.
- Non-bacterial/non-viral infection: positive fungal culture or proven parasite in concordance with clinical finding.
- Non-infectious disease: no evidence of infectious fever despite extensive supplementary diagnostics and a strong alternative diagnosis.

higher in the group with bacterial infection (p = 0.001). Unexpectedly, patients with bacterial disease had a lower pulse than patients without a bacterial disease (p < 0.001). Taking into account the severity of sepsis, the patients with more severe forms of sepsis (severe sepsis, sepsis-induced hypotension or septic shock) were significantly (p = 0.046) more likely to have bacterial infection compared with the group with sepsis alone.

Alternative diagnosis in patients without bacterial infection

To further understand how patients become misdiagnosed as possible sepsis we carefully studied the alternative diagnoses in the residual group (*table 3*). The most frequent alternative diagnosis was exacerbation of chronic obstructive pulmonary disease (COPD) with or without viral respiratory infection (n = 26). Congestive heart failure (n = 7), neutropenic fever (n = 5), pulmonary embolism (n = 4) and viral pneumonia due to H1N1 influenza (n = 4) were the most prevalent alternative diagnoses, apart from quite a large group (n = 15), in which no clear diagnosis was made.

Antibiotic use

Data regarding duration of antibiotic treatment were available for 251 patients. In the remaining patients, data could not be retrieved, for example due to transfer to another hospital.

The median duration of antibiotics for all patients was 9 days (IQR 3-15), but median 11 days (IQR 7-14) in patients with bacterial infection and 7 days (IQR 4-10 days) in patients without bacterial infections as displayed in *table 4*.

The most frequent infection was respiratory infection, which was treated for a median of 10 days. This is remarkable as evidence has shown that shorter treatments are safe and effective.¹²⁻¹⁴

Absent bacterial infection

Antibiotics were stopped in the first 5 days in only 23 (32%) of the patients without bacterial infection, see *figure 3* for more information. In this group antibiotic duration was



Lable 2. SIRS criteria and bacterial infection						
Mean (± SD)	Confirmed / suspected bacterial infection (n = 191)	Absent bacterial infection (n = 78)	P-value			
Temperature (continuous)	38,99	38,89	,475			
Normothermia (36-38 °C)	n =2 (2,5%)	n = 17 (8,9%)	,061*			
Leucocytes count (mean ± SD)	13,6 (± 7,2)	10,5 (± 5,4)	,001^			
Blood pressure (MAP)	91,9 (± 17,3)	97,7 (± 15,3)	,013^			
Systolic BP	129,3 (± 25,3)	133,5 (± 19,7)	,205^			
Diastolic BP	73,3 (± 17,8)	79,7 (± 16,1)	,007^			
Respiratory rate	24,6 (± 6,7)	23,6 (± 6,6)	,279^			
Pulse	107,8 (± 18,7)	115,6 (± 22,9)	,004			
SIRS criteria						
≤3	n = 132	n = 62	,018*			
4	n = 74	n = 17				
^ Students t-test, * Pearson c2						

Tabl	e 2.	SIRS	criteria	and	bacteria	l infection

significantly longer (p = 0.037) in patients with COPD in relation to patients with other comorbidities (current malignancy, congestive heart failure, liver cirrhosis, chronic renal insufficiency). Median duration was shortest in patients with confirmed or suspected viral disease (median 3 and 4 days, IQR 1-10.5 and 1.5-7.5).

DISCUSSION

This study demonstrates that in almost 30% of the patients with suspected sepsis in the ED no objective evidence of bacterial disease could be found. This puts patients at risk of overtreatment with antibiotics. This finding is in concordance with an earlier report of patients admitted to the ICU with a diagnosis of sepsis,¹⁵ in whom no evidence of bacterial infection could be found in 13% and only a possible infection could be established in 30%. In spite of the improved outcome of patients treated early with antibiotics for severe sepsis or septic shock, this antibiotic overtreatment in patients with sepsis is a very important finding and often underreported. It is of paramount importance to establish that patients included in sepsis research (on clinical suspicion) are in fact suffering from an infectious disease. Future research will have to report infectious outcomes in detail, to enable correct interpretation and extrapolation of the results.

Antibiotic treatment within the hour

The most important intervention in severe sepsis treatment in the last decades, next to fluid treatment, has been the emphasis on early antibiotic treatment. The problem in every ED, however, is that signs and symptoms of severe sepsis can be deceiving or occult. Postponing antibiotic treatment whilst awaiting basic test results (i.e. kidney function, chest X-ray) does not fit well within the one-hour target which has been outlined by the sepsis guidelines. The



Figure 3. Distribution of antibiotic duration among subgroups

Table 3. Final diagnosis in patients without bacterial infection					
Characteristics of patients in sepsis protocol without bacterial infection					
Clinical severity of sepsis	N = 78	Final diagnosis	N		
Sepsis	55	Arrhythmia / congestive heart failure	5		
		Exacerbation of COPD or upper respiratory infection (viral)	21		
		Neutropenic fever	3		
		Pulmonary embolism	3		
		Malignancy (tumour-related fever)	2		
		Epstein-Barr virus infection	I		
		Meningitis (viral)	Ι		
		Pericarditis (viral)	I		
		Unclear diagnosis / insufficient information	12		
Severe sepsis	20	Neutropenic fever	2		
		Fever in immunocompromised host (not neutropenic)	3		
		HINI infection / pneumonia	3		
		Viral hepatitis (Epstein-Barr virus)	I		
		Exacerbation of COPD / upper respiratory infection	5		
		Pulmonary embolism	I		
		Congestive heart failure	2		
		Unclear diagnosis / insufficient information	3		
Sepsis-induced hypotension	2	H1N1 pneumonia	I		
		Multi organ failure in a patient with new diagnosis of aggressive lymphoma (DLBCL) and history of mRCC	I		
Septic shock	I	Diabetic keto-acidosis	I		
COPD = chronic obstructive pulmonary disease: HINI = influenza of subtype HINI: DLBCL = diffuse large B-cell lymphoma: mRCC = metastatic renal					

COPD = chronic obstructive pulmonary disease; H1N1 = influenza of subtype H1N1; DLBCL = diffuse large B-cell lymphoma; mRCC = metastatic renal cell carcinoma

benefit of early antibiotic treatment has been established in suspected sepsis patients admitted to the ICU.^{1-4,16-18} Two other studies showed benefit of early antibiotic treatment in ED patients but selected only patients with sepsis and organ dysfunction or patients with hypotension/ hyperlactataemia (lactate > 4 mmol/l).¹⁹⁻²¹ However the largest group identified by our screening did not have organ dysfunction, and only about 10% needed ICU care. This means that more than half of our patients could have awaited basic test results (which might have raised suspicion of alternative diagnoses), thus allowing more time to consider if antibiotic treatment is really indicated. In pneumonia, studies have shown that treatment within four hours is safe.²² This leaves more than enough time for at least a chest X-ray and lab results to come in.

Antibiotic treatment in the ED within the hour should generally be reserved for critically ill patients, patients deteriorating quickly, or specific patient groups such as neutropenic patients. Future research will hopefully guide us further as to which risk-stratification score (Modified Early Warning Score (MEWS), National Early Warning Score (NEWS) or Quick Sequential Organ Failure Assessment (qSOFA) is most helpful with identifying patients at risk of deterioration or death.

Duration of antibiotic therapy

Overall the duration of antibiotic therapy was long in our cohort. This may reflect local standards or may be because our patients were selected in 2011.

Of concern, patients in our cohort without evidence for bacterial disease were treated with antibiotics for a median duration of 7 days, pointing to overuse. Antibiotic treatment was stopped in the first 5 days in only 32% of the patients with negative culture results. Several reasons for the prolonged use of antibiotics can be suggested.

 The ED presumptive diagnosis of sepsis makes it hard to stop antibiotics despite negative cultures. This could be due to cognitive errors such as the tendency to stick to first impressions (anchoring error) and the tendency to stick to prior diagnoses (confirmation bias) despite conflicting evidence.

- 2. The large number of patients suffering from COPD in this subgroup, in whom antibiotic treatment is often given despite negative cultures. Even so, evidence is mounting that shorter regimens are safe for bronchitis and pneumonia.¹²⁻¹⁴
- 3. Clinical improvement of patients after admission and starting antibiotics.
- Fear of undiagnosed bacterial disease by physician or patient.
- 5. Fear of inducing antimicrobial resistance if antibiotics are stopped prematurely. This is a theoretical problem which is hard to prove or refute in practice. Though widespread, it has been challenged over recent years. New research in the area of pneumonia shows that shorter treatment regimens are safe without signs of inducing microbial resistance.¹²⁻¹⁴ A review in 2016, looking at de-escalation of antimicrobials, concluded that de-escalation appears safe and effective for certain conditions, but calls for further, high-quality, research.²³ All in all, de-escalation seems safe, and if antibiotics are used for too long for fear if inducing resistance, this might actually constitute antibiotic overuse.

Limitations

Limitations of the study are its retrospective character and the single-cohort design in a single hospital. Another point of concern is the allocation of patients to groups suffering from proven/ suspected or no bacterial disease. It has been pointed out before that many patients suffering from a bacterial infection (i.e. pneumonia) may not have positive culture results. A patient suffering from urosepsis may have negative cultures due to prior treatment initiated by the primary care physician. In these patients, it is hard to determine in retrospect if they were truly suffering from bacterial disease. We have put a lot of effort into accurately determining the correct group for each patient, but in some cases it is inevitable that discussion will always remain. However, as this reflects daily practice it does not reduce our concerns of overtreatment and the protracted duration of antibiotic use.

Future investigations evaluating the sepsis campaign or regarding screening in the ED should report microbiological outcomes and include overuse and possible harm of antibiotics as endpoint to avoid a singular focus on benefits of early sepsis treatment.

Relevance and recommendations

With the new sepsis-3 definition, treatment within one hour based only on SIRS criteria cannot be substantiated. However, it is still difficult to know which patients in the ED have to be treated within the hour. qSofa was introduced as an instrument to identify patients with sepsis who are likely to fare poorly and should thus be treated early with broad-spectrum antibiotics.⁹ This is

Table 4. Antibiotic duration in subgroups					
n = 251	Duration of antibiotic treatment (median, days)	IQR			
Absent bacterial infection (n = 72)	7	4-10			
Suspected / confirmed bacterial infection ($n = 179$)					
Pulmonary (n =88)	IO	7 - 11			
Abdominal (n = 25)	7	5-12			
Urinary tract (n = 39)	IO	7-15			
Soft tissue / skin infection ($n = 15$)	13	8-14			
Endocarditis (n = 4)	35	N/A			
Joints / bone infection $(n = 3)$	9	N/A			
CNS (epidural abscess) ($n = I$)	84	N/A			
PM line associated infection $(n = I)$	42	N/A			
Ear-nose-throat $(n = I)$	8	N/A			
Bacteraemia with unknown focus $(n = 2)$	16 (mean)	N/A			
Total n = 251					

IQR = interquartile range; CNS = central nervous system; PM = pacemaker; N/A not applicable

an important step forward. However, it was noted that early treatment should not be limited to patients with a positive qSofa. Several reports have been made since, but acceptance of qSOFA is not universal. One investigation showed poor sensitivity of 63% for qSOFA in the ED population.²⁴ The same report found that the NEWS was the most accurate tool in predicting in-hospital and ICU mortality. In the UK, use of NEWS is mandatory and qSOFA has not been implemented. Since the best way to identify a septic patient in the ED is still under discussion, this study offers valuable information regarding the use of SIRS criteria.

With respect to antibiotic duration and de-escalation, the current guidelines recommend daily reconsideration of antibiotic therapy. Unfortunately, only a few studies have been performed regarding the safety of early de-escalation in patients outside the ICU. More research is needed in the area of de-escalation in suspected sepsis patients.

CONCLUSION

Sepsis detection in the ED is a continuous challenge. This study shows that early recognition of sepsis using SIRS criteria leads to over identification of sepsis. More than half of the patients suspected of sepsis would probably not fulfil the current sepsis-3 definition, and almost 30% did not have objective evidence of a bacterial infection. In some of the patients without bacterial infection, awaiting basic tests might have confirmed an alternative diagnosis and antibiotic treatment could have been avoided.

In a significant proportion of patients, empiric therapy was justified but with a median duration of therapy of seven days de-escalation should have been much more rigorous.

DISCLOSURES

All authors declare no conflict of interest. No funding or financial support was received.

REFERENTIES

- Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
- Kumar A, Roberts D, Wood KE, et al. Duration of 10 hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96
- Moore LJ, Jones SL, Kreiner LA, et al. Validation of a screening tool for the early identification of sepsis. J Trauma. 2009; 66:1539-46.
- Barie PS, Hydo LJ, Shou J, Larone DH, Eachempati SR. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt). 2005;6:41-54.

- Dellinger RP, Levy MM, Rhodes A, et al. The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving Sepsis Campaign: International Guidelines for Management of Severe sepsis and septic Shock, 2012. Intensive Care Med. 2013;39:165-228.
- Vincent JL. Dear SIRS, I'm sorry to say that I don't like you... Crit Care Med. 1997;25:372-4.
- Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372:1629-38.
- Beesley SJ, Lanspa MJ. Why we need a new definition of sepsis. Ann Transl Med. 2015;3:296.
- Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:775-8.
- Limper M, Eeftinck Schattenkerk D, de Kruif MD, et al. One year epidemiology of fever at the Emergency Department. Neth J Med. 2011;69:124-8.
- Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108-21.
- Fagalas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos I. Shortversus long-duration antmicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62:442-50.
- Li JZ, Winston LG, Moore DH, Bent S. Efficacy of Short-course antibiotic regimens for community-acquired pneumonia: A Meta-analysis. Am J Med. 2007;120:783-90.
- 14. El Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332:1355.
- Klein Klouwenberg PMC, Cremer O, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care. 2015;19:319.
- Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA, et al. Impact of the surviving sepsis protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasiexperimental study. Crit Care Med. 2010;38:1036-43.
- El Solh AA, Akinnusi ME, Alsawalha LN, et al. Outcome of septic shock in older adults after implementation of the sepsis "Bundle". J Am Geriat Soc. 2008;56:272-8.
- Puskarich MA, Trzeciak S, Shapiro MI, et al. Association between timing of antibiotic administration and mortality from septic shock inpatients treated with a quantitative resuscitation protocol. Crit Care Med. 2011;39:2066-71
- Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time of antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38: 1047-53.
- Kennedy M, Joyce N, Howell MD, Mottley JL, Shapiro NI. Identifying infected emergency department patients admitted to the hospital ward at risk of clinical deterioration and Intensive care unit transfer. Acad Emerg Med. 2010;17:1080-5.
- 21. The Australasian Resuscitation in Sepsis Evaluation (ARISE) Investigators and the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) Management Committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc. 2007;9:8-18.
- 22. Wiersinga WJ, Bonten MJ, Boersman WG, et al, for SWAB/NVALT. Guidelines Community-acquired Pneumonia. November 2011. Available through www.swab.nl
- Ohji G, Doi A, Yamamoto S, Iwata K. Is de-escalation of antimicrobials effective? A systematic review and meta-analysis. Int J Infect Dis. 2016;49:71-9.
- 24. Churpek MM, Snyder A, Han X, et al. Quick Sepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit. Am J Respir Crit Care Med. 2017;195:906-11.